Dealmaking between big pharma and biotech is an integral part of the industry ecosystem, and yet it remains as much an art as a science – and as much about personal chemistry as about drug chemistry (or biology).
Three dealmakers, two from pharma and one from biotech, came together at the Sidley Healthcare Investment Conference at the Francis Crick Institute in London on 24 September
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?